Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market ...

Evercore ISI analyst Liisa Bayko maintained a Buy rating on Altimmune (ALT – Research Report) on February 28 and set a price target of $25.00.

Shares of Altimmune Inc. (ALT) soared over 8% on Thursday, marking their best session in nearly three months, and extended ...

Q4 2024 Earnings Call Transcript February 27, 2025 Altimmune, Inc. beats earnings expectations. Reported EPS is $-0.33, ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical ...

Earnings per share (EPS) was mostly in line with analyst estimates. Looking ahead, revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 20% growth forecast for the ...

GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year ...

Altimmune Inc (ALT) reports a strong cash position and promising trial developments, despite increased expenses and ...

GAITHERSBURG, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and full ...